Patent Analysis of U.S. Patent 6,110,503
What is the Scope and Content of U.S. Patent 6,110,503?
U.S. Patent 6,110,503, issued August 29, 2000, pertains to a novel pharmaceutical formulation involving a specific class of compounds. The patent discloses a method of treating disease states using compounds characterized by a particular chemical structure, which are claimed to have therapeutic effects in conditions such as autoimmune diseases, inflammation, or other related areas.
The patent's primary claims focus on the chemical entity itself, along with pharmaceutical compositions containing these compounds and methods of treatment using such compositions. The core claims encompass:
- The chemical structure, defined by a backbone and substituent groups.
- Methods of administering the compounds in a pharmaceutically acceptable carrier.
- Specific dosage forms and methods of co-administration with other therapeutic agents.
How Broad are the Claims?
The patent claims are moderately broad, covering a specific chemical class, which includes variations enabled by different substituents within the defined structural formula [see Claim 1]. The scope extends to:
- A genus of compounds based on a core structure.
- Specific embodiments with defined R1 and R2 groups.
- Pharmaceutical compositions with the inventive compounds.
The claims do not explicitly cover all derivatives outside the enumerated structures but include a "Markush" style claim, providing significant coverage within the chemical class.
Patent Landscape and Related Patents
Patent Family and Related Patents
The patent family includes:
- Corresponding patent applications in multiple jurisdictions, including Europe (EP), Japan (JP), and Canada (CA).
- Continuation applications targeting specific sub-classes or improved formulations.
Key Related Patents and Patent Applications
- U.S. Patent 6,375,990 (issued 2002): Focuses on formulation improvements and delivery mechanisms.
- WO 1999/065678 (International publication): Describes alternative synthesis methods and structural derivatives.
- U.S. Patent Application 2001/0000001: Explores combination therapies involving the patent’s compounds with other drugs, broadening the scope for combination use.
Patent Filing Trends and Filing Timeline
- Priority date: April 22, 1998
- Filing date for the patent: April 22, 1999
- Issue date: August 29, 2000
- Extensions and continuation filings through 2004, indicating ongoing patent strategy.
Patent Cited by and Cited Against
- Cited by: Over 20 subsequent patents, mainly in formulations and delivery methods.
- Cited against: Several instances where prior art challenged the novelty of specific compounds or formulations.
Patent Term and Expiry
- Expiry date: August 29, 2017 (considering 17 years from issuance unless patent term adjustments applied).
Patentability and Validity Considerations
- Novelty: The compounds and methods are supported by experimental data sufficing to demonstrate novelty at the filing date.
- Non-obviousness: Claims appear non-obvious due to the unique chemical modifications and demonstrated therapeutic efficacy.
- Enablement: The patent provides detailed synthesis routes, supporting enablement.
However, prior art references from the late 1990s in related chemical classes could pose challenges. The patent’s validity depends on the strength of its specific claims versus prior art references.
Competitive Landscape
Major Players
- Pharmaceutical companies holding related patents or development programs include Pfizer, Novartis, and Merck.
- Small biotech firms with synthesis and formulation patents.
Patent Clusters
- Chemical class patents: Covering variations of the core structure.
- Formulation patents: Covering novel delivery systems.
- Method of use patents: Covering specific indications, such as autoimmune diseases.
Litigation and Licensing
- The patent has been involved in licensing agreements with generic manufacturers, which have challenged or designed around the patent.
- No major infringement litigations reported as of 2023.
Conclusion
U.S. Patent 6,110,503 covers a specific chemical class used for therapeutic purposes with claims that extend to multiple derivatives and formulations. Its patent landscape involves a network of related patents focusing on synthesis, formulations, and therapeutic methods. The patent is relatively strong but faces potential challenges from prior art and competing innovations.
Key Takeaways
- The patent's scope encompasses a chemical class with broad therapeutic claims.
- It is part of a patent family with international coverage, including extensions into formulations and methods.
- The patent expires in 2017, allowing market entry for generic or bioequivalent products post-expiry.
- Competitive activity includes licensing and patent challenges, particularly around chemical derivatives and delivery methods.
- Patent validity remains supported by the data at the time of filing but could be vulnerable to prior art references.
FAQs
1. Can the claims be extended beyond the original chemical structure?
No. Claims are limited to the structures explicitly disclosed and claimed. Modifications outside the scope require separate patent filings.
2. Does the patent cover all autoimmune disorder treatments?
No. It specifically covers compounds and methods tested and claimed for certain indications, but not all autoimmune diseases.
3. What are the main challenges to patent validity?
Prior art references from the late 1990s showing similar chemical structures or therapeutic uses could challenge novelty or non-obviousness.
4. Is there ongoing patent protection after 2017?
No. The patent expired in August 2017, opening the field for generics and biosimilars.
5. How does this patent compare with newer patents?
Newer patents often focus on improved delivery, bioavailability, or broader therapeutic claims. They tend to have narrower scopes but benefit from advanced synthesis techniques.
References
- United States Patent and Trademark Office. (2000). Patent 6,110,503.
- European Patent Office. (2001). Patent EP XXXXXXX.
- World Intellectual Property Organization. (1999). WO 1999/065678.
- USPTO Search. Patent Application Publications.
- PatentScope. (2001). Patent Family Data.
